Literature DB >> 21252049

Innate immunity in alcoholic liver disease.

Bin Gao1, Ekihiro Seki, David A Brenner, Scott Friedman, Jessica I Cohen, Laura Nagy, Gyongyi Szabo, Samir Zakhari.   

Abstract

Excessive alcohol consumption is a leading cause of chronic liver disease in the Western world. Alcohol-induced hepatotoxicity and oxidative stress are important mechanisms contributing to the pathogenesis of alcoholic liver disease. However, emerging evidence suggests that activation of innate immunity involving TLR4 and complement also plays an important role in initiating alcoholic steatohepatitis and fibrosis, but the role of adaptive immunity in the pathogenesis of alcoholic liver disease remains obscure. Activation of a TLR4-mediated MyD88-independent (TRIF/IRF-3) signaling pathway in Kupffer cells contributes to alcoholic steatohepatitis, whereas activation of TLR4 signaling in hepatic stellate cells promotes liver fibrosis. Alcohol consumption activates the complement system in the liver by yet unidentified mechanisms, leading to alcoholic steatohepatitis. In contrast to activation of TLR4 and complement, alcohol consumption can inhibit natural killer cells, another important innate immunity component, contributing to alcohol-mediated acceleration of viral infection and liver fibrosis in patients with chronic viral hepatitis. Understanding of the role of innate immunity in the pathogenesis of alcoholic liver disease may help us identify novel therapeutic targets to treat this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252049      PMCID: PMC3774265          DOI: 10.1152/ajpgi.00537.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  128 in total

Review 1.  Kupffer cells and alcoholic liver disease.

Authors:  F J Cubero; N Nieto
Journal:  Rev Esp Enferm Dig       Date:  2006-06       Impact factor: 2.086

Review 2.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

3.  Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis.

Authors:  Hong-na Pan; Rui Sun; Barbara Jaruga; Feng Hong; Won-Ho Kim; Bin Gao
Journal:  Alcohol Clin Exp Res       Date:  2006-09       Impact factor: 3.455

4.  CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice.

Authors:  Tomonori Aoyama; Sayaka Inokuchi; David A Brenner; Ekihiro Seki
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

5.  Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase.

Authors:  J F Lawler; M Yin; A M Diehl; E Roberts; S Chatterjee
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

6.  Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury.

Authors:  Zubin M Bamboat; Vinod P Balachandran; Lee M Ocuin; Hebroon Obaid; George Plitas; Ronald P DeMatteo
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

8.  Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis.

Authors:  Won-Il Jeong; Ogyi Park; Bin Gao
Journal:  Gastroenterology       Date:  2007-09-29       Impact factor: 22.682

9.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Authors:  Golo Ahlenstiel; Rachel H Titerence; Christopher Koh; Birgit Edlich; Jordan J Feld; Yaron Rotman; Marc G Ghany; Jay H Hoofnagle; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

Review 10.  Neutrophilic infiltration in alcoholic hepatitis.

Authors:  Abraham P Bautista
Journal:  Alcohol       Date:  2002-05       Impact factor: 2.405

View more
  100 in total

Review 1.  Binge drinking: Burden of liver disease and beyond.

Authors:  Susana Llerena; María Teresa Arias-Loste; Angela Puente; Joaquín Cabezas; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2015-11-28

2.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

Review 3.  Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes.

Authors:  Laura E Nagy; Wen-Xing Ding; Gail Cresci; Paramananda Saikia; Vijay H Shah
Journal:  Gastroenterology       Date:  2016-02-23       Impact factor: 22.682

4.  Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease.

Authors:  Jan Petrasek; Arvin Iracheta-Vellve; Banishree Saha; Abhishek Satishchandran; Karen Kodys; Katherine A Fitzgerald; Evelyn A Kurt-Jones; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2015-05-01       Impact factor: 4.962

5.  Dietary saturated fatty acids reduce hepatic lipid accumulation but induce fibrotic change in alcohol-fed rats.

Authors:  Ya-Ling Chen; Hsiang-Chi Peng; Xiang-Dong Wang; Suh-Ching Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

6.  Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use.

Authors:  Terence Ndonyi Bukong; Yeonhee Cho; Arvin Iracheta-Vellve; Banishree Saha; Patrick Lowe; Adeyinka Adejumo; Istvan Furi; Aditya Ambade; Benedek Gyongyosi; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  J Hepatol       Date:  2018-07-18       Impact factor: 25.083

7.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

8.  Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats.

Authors:  Hui Qian; Jian Shi; Ting-Ting Fan; Jiao Lv; Si-Wen Chen; Chun-Yan Song; Zhi-Wu Zheng; Wei-Fen Xie; Yue-Xiang Chen
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Authors:  Alexander Wree; Matthew D McGeough; Maria Eugenia Inzaugarat; Akiko Eguchi; Susanne Schuster; Casey D Johnson; Carla A Peña; Lukas J Geisler; Bettina G Papouchado; Hal M Hoffman; Ariel E Feldstein
Journal:  Hepatology       Date:  2017-12-28       Impact factor: 17.425

Review 10.  Management of alcohol misuse in patients with liver diseases.

Authors:  Jennifer L Peng; Milan Prakash Patel; Breann McGee; Tiebing Liang; Kristina Chandler; Sucharat Tayarachakul; Sean O'Connor; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-12-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.